This product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the GTSE1 gene in the human NCI-H1975 lung adenocarcinoma cell line. It provides a loss-of-function model for studying GTSE1-mediated regulation of cell cycle progression and apoptosis. The polyclonal nature offers a heterogeneous pool of edited cells, suitable for pooled screening and population-level analyses.
NCI-H1975 is a widely used NSCLC model derived from a female patient with non-small cell lung adenocarcinoma. It harbors activating EGFR L858R and T790M mutations, conferring dependence on EGFR signaling and sensitivity to EGFR tyrosine kinase inhibitors. These cells are adherent, epithelial, and commonly employed in drug resistance and oncogenic signaling studies.
GTSE1 encodes a microtubule-binding protein that localizes to the centrosome and regulates the G2/M transition. Mechanistically, GTSE1 acts as a negative regulator of the tumor suppressor p53 by sequestering it in the cytoplasm, thereby inhibiting p53-dependent transcription of pro-apoptotic genes such as BAX and PUMA. This function is crucial for cell survival following genotoxic stress. GTSE1 is regulated by E2F transcription factors and is phosphorylated by PLK1 kinase, which modulates its activity during cell cycle progression. Additionally, DNA damage signals via ATM/ATR can influence GTSE1 stability, linking it to the DNA damage response. GTSE1 interacts with p53, PLK1, MDM2, ??-tubulin, and the mitotic kinase MPS1 (TTK), positioning it at the intersection of cell cycle control and apoptosis. Downstream, GTSE1 suppression leads to upregulation of CDKN1A (p21) and promotes apoptotic signaling, underscoring its role in maintaining proliferation under stress.
In the context of NCI-H1975 cells, GTSE1 knockout is particularly relevant for dissecting mechanisms of chemoresistance in EGFR-mutant lung adenocarcinoma. Elevated GTSE1 expression has been associated with poor prognosis and resistance to DNA-damaging agents such as cisplatin. By disrupting GTSE1, researchers can investigate how loss of this protein affects p53 reactivation, apoptosis induction, and sensitivity to EGFR inhibitors and chemotherapeutics. This model also allows exploration of PLK1-mediated signaling and its interplay with DNA damage checkpoints in a clinically relevant background.
This polyclonal knockout product is suited for a broad range of assays. Western blotting and RT-qPCR can confirm GTSE1 disruption and monitor expression changes in p53, p21, and ??H2AX. Immunofluorescence enables visualization of alterations in microtubule morphology and p53 nuclear translocation. Flow cytometry facilitates cell cycle analysis and apoptosis quantification. Functional studies such as colony formation, wound healing, and xenograft tumor growth assays provide insights into tumorigenic potential. Drug sensitivity testing with cisplatin or EGFR inhibitors evaluates chemoresistance mechanisms. For further details or personalized support, contact Ascent Research.
